Business Wire

XPRIZE Announces New $10 Million Competition to Preserve Rainforests Across the Globe

19.11.2019 15:00:00 EET | Business Wire | Press release

Share

Today, XPRIZE, the global leader in designing and operating incentive competitions to solve humanity’s grand challenges, officially launched the $10M Rainforest XPRIZE. Registration is now open for teams interested in participating in the four-year global competition that calls on innovators to create technology capable of identifying and cataloging rainforest biodiversity and develop insights that may lead to a new bioeconomy through standing forests.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191119005397/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

(Graphic: Business Wire)

Rainforests remain undervalued, which has led to their rapid depletion over the past two decades. Having once covered 14% of the earth’s land surface, rainforests now cover a mere 6% of the planet, according to National Geographic. Specifically, the recent acceleration of the Amazon’s deforestation, due in part to illegal logging and mining as well as inefficient agricultural expansion, has added to climate insecurity around the globe. All these factors have elevated the urgency of bringing the importance of preserving these precious ecosystems to the forefront of international discourse. Knowledge of the full biodiversity must be unlocked so that private companies, corporations, governments, individuals, local communities, and indigenous people who have demonstrated a commitment to preserving the rainforests will be empowered to sustain rainforests rather than destroy them.

The Rainforest XPRIZE will reward teams that can develop effective new technology to capture the true biological diversity of rainforests and further layer additional data to show the value of protecting the natural resources within them. The current methods used to identify and catalogue biodiversity, including in situ human-led studies, remote sensing by satellites or radar, or sophisticated spectroscopy, cannot operate to scale and gather the data necessary to understand the full ecosystem wealth of rainforests in sustainable ways. The competition accelerates a new bioeconomy, while also engaging indigenous and local communities, as well as local academic institutions in developing the solution. The Rainforest XPRIZE is a call-to-action to help save rainforests through the development and implementation of transformative, scalable, and affordable technology.

Anousheh Ansari, CEO of XPRIZE, said, “Amid our 25th anniversary as an organization, it is fitting that we add to our legacy by introducing a prize that will challenge the best and brightest to develop transformative technology to incentivize the preservation of rainforests worldwide, not only for our generation, but those to follow.”

“Despite their importance in supporting life on Earth, rainforests are undervalued because we simply do not yet know everything that exists in this ancient ecosystem,” said Executive Director of the Rainforest XPRIZE Jyotika Virmani, Ph.D. “I’m excited to see the innovative technologies that will emerge from this competition and give us a better assessment of the incredible biodiversity. Our goal is for the Rainforest XPRIZE to provide new understanding and reveal the true potential of the standing forest, allowing local communities to lead the way for all of us to live in harmony with these magnificent rainforests.”

The teams of the Rainforest XPRIZE will develop sophisticated technologies to inventory rainforest biodiversity faster, affordably, and in unprecedented detail in challenging harsh environments, delivering insights to support the sustainable use and well-being of the standing forest. Interdisciplinary teams can use emerging technologies such as robotics, remote sensing, data analysis, artificial intelligence, and machine learning to survey biodiversity, deal with the challenges of a harsh environment, and demonstrate that these ecosystems are worth preserving.

Specifically, the winning team will survey biodiversity in at least three stories of a rainforest (emergent, canopy, understory, and forest floor) in eight hours to produce the most comprehensive biodiversity assessment and utilize this and other data to produce the greatest number of insights in 48 hours. Insights may include, but are not limited to, new ecological dependencies, biodiversity and climate connectivity, anthropological findings, or even sustainable societal interactions with the forest.

The competition includes seven months for team registration and three months for initial technical document submission. A total prize purse of $10M will be awarded throughout the lifespan of the prize, including up to $500K in bonus prizes for innovative approaches to species identification. Milestone prizes will also be awarded equally for up to 10 final teams that advance through the semi-finals.

Throughout the life cycle of the competition and following the grand prize awards ceremony, XPRIZE will work to support and scale the impact of the teams’ work and promote education around rainforest preservation.

The Rainforest XPRIZE originated from Future of Forests Impact Roadmap. The Future of Forests Impact Roadmap identified six areas for breakthroughs that could usher in a preferred future for the world’s forests, one in which forests live in harmony in an environment that balances a healthy ecosystem with humanity’s changing needs, including economic growth, social progress, and political stability.

The deadline for teams to register through the XPRIZE website is June 30, 2020. Beginning July 1, 2020 to September 23, 2020 teams can request late registration, that will be at the discretion of XPRIZE. For more information, and to register your intent to compete, visit rainforest.xprize.org.

XPRIZE

XPRIZE designs and operates multi-million-dollar, global competitions to incentivize the development of technological breakthroughs that accelerate humanity toward a better future. Active competitions include the $20 Million NRG COSIA Carbon XPRIZE, the $10 Million ANA Avatar XPRIZE and the $5 Million IBM Watson AI XPRIZE. For more information, visit xprize.org.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Katherine Schelbert
katherine.schelbert@xprize.org

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release

For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye